Abstract
Ewing sarcomas (ES) are highly malignant bone or soft tissue tumors. Genetically, ES are defined by balanced chromosomal EWS/ETS translocations, which give rise to chimeric proteins (EWS-ETS) that generate an oncogenic transcriptional program associated with altered epigenetic marks throughout the genome. By use of an inhibitor (JQ1) blocking BET bromodomain binding proteins (BRDs) we strikingly observed a strong down-regulation of the predominant EWS-ETS protein EWS-FLI1 in a dose dependent manner. This was further enhanced by co-treatment with an inhibitor of the PI3K pathway. Microarray analysis further revealed JQ1 treatment to block a typical ES associated expression program. The effect on this expression program was mimicked by RNA interference with BRD3 or BRD4 expression, indicating that the EWS-FLI1 mediated expression profile is at least in part mediated via such epigenetic readers. Consequently, contact dependent and independent proliferation of different ES lines was strongly inhibited. Mechanistically, treatment of ES resulted in a partial arrest of the cell cycle as well as induction of apoptosis. Tumor development was suppressed dose dependently in a xeno-transplant model in immune deficient mice, overall indicating that ES may be susceptible to treatment with epigenetic inhibitors blocking BET bromodomain activity and the associated pathognomonic EWS-ETS transcriptional program.
Keywords:
BET bromodomains; Ewing sarcoma; JQ1; PI3K pathway; tumor growth.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Apoptosis / drug effects
-
Azepines / pharmacology*
-
Bone Neoplasms / drug therapy*
-
Bone Neoplasms / genetics
-
Bone Neoplasms / metabolism
-
Bone Neoplasms / pathology
-
Cell Cycle / drug effects
-
Cell Cycle Proteins
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Dose-Response Relationship, Drug
-
Down-Regulation
-
Epigenesis, Genetic
-
Gene Expression Profiling
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Mice, Inbred BALB C
-
Mice, Knockout
-
Molecular Targeted Therapy
-
Nuclear Proteins / antagonists & inhibitors*
-
Nuclear Proteins / genetics
-
Nuclear Proteins / metabolism
-
Oncogene Proteins, Fusion / genetics
-
Oncogene Proteins, Fusion / metabolism*
-
Phosphatidylinositol 3-Kinase / metabolism
-
Phosphoinositide-3 Kinase Inhibitors
-
Protein Kinase Inhibitors / pharmacology
-
Proto-Oncogene Protein c-fli-1 / genetics
-
Proto-Oncogene Protein c-fli-1 / metabolism*
-
RNA Interference
-
RNA-Binding Protein EWS / genetics
-
RNA-Binding Protein EWS / metabolism*
-
RNA-Binding Proteins / antagonists & inhibitors*
-
RNA-Binding Proteins / genetics
-
RNA-Binding Proteins / metabolism
-
Sarcoma, Ewing / drug therapy*
-
Sarcoma, Ewing / genetics
-
Sarcoma, Ewing / metabolism
-
Sarcoma, Ewing / pathology
-
Signal Transduction / drug effects
-
Time Factors
-
Transcription Factors / antagonists & inhibitors*
-
Transcription Factors / genetics
-
Transcription Factors / metabolism
-
Transcription, Genetic / drug effects*
-
Transfection
-
Triazoles / pharmacology*
-
Tumor Burden / drug effects
-
Xenograft Model Antitumor Assays
Substances
-
(+)-JQ1 compound
-
Antineoplastic Agents
-
Azepines
-
BRD3 protein, human
-
BRD4 protein, human
-
Cell Cycle Proteins
-
EWS-FLI fusion protein
-
Nuclear Proteins
-
Oncogene Proteins, Fusion
-
Phosphoinositide-3 Kinase Inhibitors
-
Protein Kinase Inhibitors
-
Proto-Oncogene Protein c-fli-1
-
RNA-Binding Protein EWS
-
RNA-Binding Proteins
-
Transcription Factors
-
Triazoles
-
Phosphatidylinositol 3-Kinase